Telix Pharmaceuticals Statistics

Total Valuation

Telix Pharmaceuticals has a market cap or net worth of 6.12 billion. The enterprise value is 5.97 billion.

Market Cap	6.12B
Enterprise Value	5.97B

Important Dates

The next estimated earnings date is Wednesday, August 21, 2024.

Earnings Date	Aug 21, 2024
Ex-Dividend Date	n/a

Share Statistics

Telix Pharmaceuticals has 323.73 million shares outstanding. The number of shares has increased by 14.39% in one year.

Shares Outstanding	323.73M
Shares Change (YoY)	+14.39%
Shares Change (QoQ)	+1.92%
Owned by Insiders (%)	41.49%
Owned by Institutions (%)	12.55%
Float	254.75M

Valuation Ratios

The trailing PE ratio is 922.00 and the forward PE ratio is 21.01.

PE Ratio	922.00
Forward PE	21.01
PS Ratio	12.10
PB Ratio	40.83
P/FCF Ratio	464.45
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 102.23, with an EV/FCF ratio of 456.37.

EV / Earnings	1,146.40
EV / Sales	11.89
EV / EBITDA	102.23
EV / EBIT	115.97
EV / FCF	456.37

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.12.

Current Ratio	1.43
Quick Ratio	1.19
Debt / Equity	0.12
Debt / EBITDA	0.30
Debt / FCF	1.33
Interest Coverage	-1,776.31

Financial Efficiency

Return on equity (ROE) is 3.50% and return on invested capital (ROIC) is 52.27%.

Return on Equity (ROE)	3.50%
Return on Assets (ROA)	1.31%
Return on Capital (ROIC)	52.27%
Revenue Per Employee	1.21M
Profits Per Employee	12,557
Employee Count	415
Asset Turnover	1.42
Inventory Turnover	17.36

Taxes

Income Tax	-2.12M
Effective Tax Rate	-68.80%

Stock Price Statistics

The stock price has increased by +65.02% in the last 52 weeks. The beta is 2.43, so Telix Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	2.43
52-Week Price Change	+65.02%
50-Day Moving Average	16.30
200-Day Moving Average	12.17
Relative Strength Index (RSI)	60.13
Average Volume (20 Days)	1,420,939

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Telix Pharmaceuticals had revenue of 502.55 million and earned 5.21 million in profits. Earnings per share was 0.02.

Revenue	502.55M
Gross Profit	314.79M
Operating Income	51.51M
Pretax Income	3.09M
Net Income	5.21M
EBITDA	58.44M
EBIT	51.51M
Earnings Per Share (EPS)	0.02

Full Income Statement

Balance Sheet

The company has 123.24 million in cash and 17.45 million in debt, giving a net cash position of 105.79 million or 0.33 per share.

Cash & Cash Equivalents	123.24M
Total Debt	17.45M
Net Cash	105.79M
Net Cash Per Share	0.33
Equity (Book Value)	148.91M
Book Value Per Share	0.46
Working Capital	67.44M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 23.88 million and capital expenditures -10.79 million, giving a free cash flow of 13.09 million.

Operating Cash Flow	23.88M
Capital Expenditures	-10.79M
Free Cash Flow	13.09M
FCF Per Share	0.04

Full Cash Flow Statement

Margins

Gross margin is 62.64%, with operating and profit margins of 10.25% and 1.04%.

Gross Margin	62.64%
Operating Margin	10.25%
Pretax Margin	0.61%
Profit Margin	1.04%
EBITDA Margin	11.63%
EBIT Margin	10.25%
FCF Margin	2.60%

Dividends & Yields

Telix Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.39%
Shareholder Yield	-14.39%
Earnings Yield	0.09%
FCF Yield	0.22%

Analyst Forecast

Price Target	18.89
Price Target Difference	3.11%
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a